Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.

objective
To compare the efficacy of platinum and non-platinum-based regimens as first-line treatment for triple-negative breast cancer is advanced (TNBC) and analyze the relationship between their success and status of the BRCA genes.


method
Retrospectively analyzed clinical data from 220 patients diagnosed with advanced pathological TNBC and treated in the Department of Breast Oncology, Peking University Cancer Hospital from 2013 to 2018 and evaluate the effectiveness of chemotherapy. A total of 114 patients had BRCA1 / 2 genes were tested by next generation sequencing (NGS) using peripheral blood, and we analyzed the correlation between efficacy and BRCA1 / 2 gene status.


result
non-platinum-based chemotherapy (NPCT) was given to 129 and platinum-based chemotherapy (PBCT) to 91 study patients. The level of clinical benefit (CBR) and median progression-free survival (PFS) were not statistically different between groups NPCT and PBCT. Overall average life (OS) was 30.0 and 22.5 months for PBCT and NPCT groups, respectively [P = 0.090, hazard ratio (HR) = 0.703]. BRCA status assessed 114 patients, 14 of whom have a detrimental germline BRCA1 / 2 (gBRCA) mutation (seven in each group). In PBCT group, CBR was 85.7% and 35.1% for patients with and without mutations that destroy gBRCA, respectively (P = 0.039). Median PFS was 14.9 and 5.3 months and the median OS was 26.5 and 15.5 months for patients with and without mutations that destroy gBRCA, respectively (P = 0.001, P = 0.161, respectively). Patients in group PBCT have significantly greater levels of grade 3-4 anemia (5.5% vs. 0%) and thrombocytopenia (8.8% vs 0%), while the palmar-plantar erythrodysesthesia (12.4% vs 0% ) and peripheral neuropathy (8.6% vs. 1.1%) occurred more frequently in the group NPCT.

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.


conclusion
platinum-based regimen was more effective in patients with mutations gBRCA damage, but there was no difference in patients without BRCA gene mutation, so that the non-platinum is an option in patients without BRCA gene mutation consider the toxicity and side effects. And we suggest that patients with advanced TNBC must have a BRCA gene test.

TAME Hydrochloride

2050-500
EUR 338

Verapamil hydrochloride

2861-1G
EUR 131

Verapamil hydrochloride

2861-5G
EUR 327

Ticlopidine hydrochloride

2919-25
EUR 403

Ticlopidine hydrochloride

2919-5
EUR 153

EHNA hydrochloride

2265-25
EUR 283

EHNA hydrochloride

2265-5
EUR 115

AdipoRon hydrochloride

2572-25
EUR 588

AdipoRon hydrochloride

2572-5
EUR 185

Pargyline hydrochloride

2618-1000
EUR 175

Pargyline hydrochloride

2618-500
EUR 120

Clorgyline hydrochloride

2622-10
EUR 120

Clorgyline hydrochloride

2622-50
EUR 327

Clindamycin hydrochloride

2627-10
EUR 131

Clindamycin hydrochloride

2627-50
EUR 370

Loperamide hydrochloride

2683-1000
EUR 185

Loperamide hydrochloride

2683-500
EUR 131

Clonidine hydrochloride

2684-100
EUR 131

Clonidine hydrochloride

2684-500
EUR 359

Leelamine hydrochloride

2717-25
EUR 457

Leelamine hydrochloride

2717-5
EUR 153

SBE13 hydrochloride

2847-10
EUR 185

SBE13 hydrochloride

2847-50
EUR 588

Amodiaquine hydrochloride

A085-5G 5 g
EUR 55

Metformin, Hydrochloride

1691-5G
EUR 158

Irinotecan Hydrochloride

1752-250
EUR 387

Irinotecan Hydrochloride

1752-50
EUR 147

Epirubicin Hydrochloride

1753-25
EUR 457

Epirubicin Hydrochloride

1753-5
EUR 158

Gemcitabine Hydrochloride

1759-100
EUR 370

Gemcitabine Hydrochloride

1759-25
EUR 156

Amiodarone Hydrochloride

1828-100
EUR 126

Amiodarone Hydrochloride

1828-500
EUR 338

Phenformin hydrochloride

1889-100
EUR 115

Phenformin hydrochloride

1889-1000
EUR 359

Tomatidine hydrochloride

1893-25
EUR 137

Vancomycin Hydrochloride

B1507-1G
EUR 153

Vancomycin Hydrochloride

B1507-250
EUR 120

Vancomycin Hydrochloride

B1507-5G
EUR 262

Lincomycin Hydrochloride

B1524-1G
EUR 142

Lincomycin Hydrochloride

B1524-5G
EUR 403

Minocycline Hydrochloride

B1525-250
EUR 414

Minocycline Hydrochloride

B1525-50
EUR 142

Oxytetracycline Hydrochloride

B1527-25G
EUR 229

Oxytetracycline Hydrochloride

B1527-5G
EUR 109

Tetracycline Hydrochloride

B1535-10G
EUR 109

Tetracycline Hydrochloride

B1535-50G
EUR 196

Hydroxyfasudil Hydrochloride

B1559-25
EUR 631

Hydroxyfasudil Hydrochloride

B1559-5
EUR 196

Thioridazine Hydrochloride

B1581-1G
EUR 120

Thioridazine Hydrochloride

B1581-5G
EUR 327

Ivabradine Hydrochloride

B1595-10
EUR 142

Bendamustine Hydrochloride

B1596-25
EUR 457

Bendamustine Hydrochloride

B1596-5
EUR 153

Afuresertib hydrochloride

B1848-5
EUR 175

Chlorpromazine hydrochloride

B1992-100
EUR 120

Chlorpromazine hydrochloride

B1992-500
EUR 294

Triflupromazine hydrochloride

B1993-100
EUR 120

 ZLN024 hydrochloride

B2034-25
EUR 588

 ZLN024 hydrochloride

B2034-5
EUR 185

Topotecan hydrochloride

B2050-10
EUR 131

Givinostat hydrochloride

B2081-25
EUR 756

Givinostat hydrochloride

B2081-5
EUR 229

Moexipril hydrochloride

B2134-25
EUR 294

Imidapril hydrochloride

B2135-25
EUR 414

Imidapril hydrochloride

B2135-5
EUR 142

Benazepril hydrochloride

B2138-250
EUR 294

Benazepril hydrochloride

B2138-50
EUR 131

Dorzolamide hydrochloride

B2185-10
EUR 120

Dorzolamide hydrochloride

B2185-50
EUR 327

Eltoprazine hydrochloride

B2301-25
EUR 457

Eltoprazine hydrochloride

B2301-5
EUR 153

Papaverine hydrochloride

B2315-250
EUR 262

Papaverine hydrochloride

B2315-50
EUR 120

Sarecycline hydrochloride

B2383-25
EUR 588

Sarecycline hydrochloride

B2383-5
EUR 185

Sertraline (hydrochloride)

B2393-10
EUR 131

Sertraline (hydrochloride)

B2393-50
EUR 327

Migalastat hydrochloride

B2404-25
EUR 756

Migalastat hydrochloride

B2404-5
EUR 229

Butenafine hydrochloride

B2421-250
EUR 327

Butenafine hydrochloride

B2421-50
EUR 120

Naftifine hydrochloride

B2422-10
EUR 131

Naftifine hydrochloride

B2422-50
EUR 349

Rilpivirine hydrochloride

B2427-25
EUR 414

Rilpivirine hydrochloride

B2427-5
EUR 142

Tirabrutinib hydrochloride

B2556-25
EUR 457

Tirabrutinib hydrochloride

B2556-5
EUR 153

Robenidine hydrochloride

B2560-1G
EUR 131

Robenidine hydrochloride

B2560-5G
EUR 262

Sardomozide Hydrochloride

B2566-25
EUR 631

Sardomozide Hydrochloride

B2566-5
EUR 196

Riviciclib hydrochloride

B2567-1
EUR 142

Riviciclib hydrochloride

B2567-5
EUR 414

CPTH2 (hydrochloride)

B2815-1
EUR 120

CPTH2 (hydrochloride)

B2815-5
EUR 294

Resminostat (hydrochloride)

B2852-25
EUR 588

Resminostat (hydrochloride)

B2852-5
EUR 185

Almorexant hydrochloride

B3241-10 10 mg
EUR 440
Description: Almorexant is an antagonist of Orexin 1 receptor (OX1R) and Orexin 2 receptor (OX2R) with Kd values of 1.3nM and 0.17nM, respectively [1].

Almorexant hydrochloride

B3241-5 5 mg
EUR 270
Description: Almorexant is an antagonist of Orexin 1 receptor (OX1R) and Orexin 2 receptor (OX2R) with Kd values of 1.3nM and 0.17nM, respectively [1].

Memantine hydrochloride

B3308-200 200 mg
EUR 137
Description: Memantine hydrochloride is an antagonist of NMDA receptor with IC50 values of 0.93?M, 0.82?M and 0.47?M for NRIa/NR2A, NRIa/NR2B and NRIa/NR2D, respectively [1].

Memantine hydrochloride

B3308-5.1 10 mM (in 1mL DMSO)
EUR 113
Description: Memantine hydrochloride is an antagonist of NMDA receptor with IC50 values of 0.93?M, 0.82?M and 0.47?M for NRIa/NR2A, NRIa/NR2B and NRIa/NR2D, respectively [1].

Memantine hydrochloride

B3308-S Evaluation Sample
EUR 81
Description: Memantine hydrochloride is an antagonist of NMDA receptor with IC50 values of 0.93?M, 0.82?M and 0.47?M for NRIa/NR2A, NRIa/NR2B and NRIa/NR2D, respectively [1].

Cyproheptadine hydrochloride

B3309-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Cyproheptadine hydrochloride is an antagonist of serotonin receptor [1]. Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent.

Cyproheptadine hydrochloride

B3309-50 50 mg
EUR 128
Description: Cyproheptadine hydrochloride is an antagonist of serotonin receptor [1]. Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent.

Cyproheptadine hydrochloride

B3309-S Evaluation Sample
EUR 81
Description: Cyproheptadine hydrochloride is an antagonist of serotonin receptor [1]. Cyproheptadine is a serotonin and histamine antagonist as well as an antimuscarinic reagent.

Moxonidine hydrochloride

B3314-10 10 mg
EUR 195
Description: Moxonidine hydrochloride is a mixed agonist of ?2-adrenergic receptor (?2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L.

Moxonidine hydrochloride

B3314-100 100 mg
EUR 864
Description: Moxonidine hydrochloride is a mixed agonist of ?2-adrenergic receptor (?2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L.

Moxonidine hydrochloride

B3314-50 50 mg
EUR 502
Description: Moxonidine hydrochloride is a mixed agonist of ?2-adrenergic receptor (?2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L.

Bupropion hydrochloride

B3326-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Bupropion hydrochloride is a dual effective inhibitor of norepinephrine and dopamine neurotransmitter with the IC50 values of 6.5 ± 0.6?M and 3.4 ± 0.4 ?M, respectively [1].

Bupropion hydrochloride

B3326-50 50 mg
EUR 128
Description: Bupropion hydrochloride is a dual effective inhibitor of norepinephrine and dopamine neurotransmitter with the IC50 values of 6.5 ± 0.6?M and 3.4 ± 0.4 ?M, respectively [1].

Bupropion hydrochloride

B3326-S Evaluation Sample
EUR 81
Description: Bupropion hydrochloride is a dual effective inhibitor of norepinephrine and dopamine neurotransmitter with the IC50 values of 6.5 ± 0.6?M and 3.4 ± 0.4 ?M, respectively [1].

Sotalol hydrochloride

B3341-100 100 mg
EUR 139
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].

Sotalol hydrochloride

B3341-200 200 mg
EUR 187
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].

Sotalol hydrochloride

B3341-5.1 10 mM (in 1mL DMSO)
EUR 119
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].

Sotalol hydrochloride

B3341-50 50 mg
EUR 106
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].

Sotalol hydrochloride

B3341-S Evaluation Sample
EUR 81
Description: Sotalol hydrochloride is a potent and non-selective antagonist of ?-adrenergic receptor. Sotalol is also an inhibitor of potassinm channels with the IC50 value of ~1.2mM in HEK cell lines [1].

Miglustat hydrochloride

B3402-10 10 mg
EUR 312
Description: Miglustat Hhydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Miglustat hydrochloride

B3402-25 25 mg
EUR 641
Description: Miglustat Hhydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Miglustat hydrochloride

B3402-5 5 mg
EUR 195
Description: Miglustat Hhydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).

Solifenacin hydrochloride

B3415-10 10 mg
EUR 321
Description: Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.

Solifenacin hydrochloride

B3415-100 100 mg
EUR 1407
Description: Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.

Solifenacin hydrochloride

B3415-5 5 mg
EUR 231
Description: Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.

Solifenacin hydrochloride

B3415-5.1 10 mM (in 1mL DMSO)
EUR 248
Description: Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.

Solifenacin hydrochloride

B3415-50 50 mg
EUR 864
Description: Solifenacin Hcl(YM905 Hcl; Vesicare Hcl) is a muscarinic receptor antagonist.

Vigabatrin Hydrochloride

B3421-10 10 mg
EUR 142
Description: Vigabatrin Hcl(?-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.

Vigabatrin Hydrochloride

B3421-25 25 mg
EUR 270
Description: Vigabatrin Hcl(?-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.

Vigabatrin Hydrochloride

B3421-50 50 mg
EUR 440
Description: Vigabatrin Hcl(?-Vinyl-GABA; Sabril) is a structural analog of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) that irreversibly inhibits the catabolism of GABA by GABA transaminase.

Flavoxate hydrochloride

B3433-5 5 mg
EUR 131
Description: Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.

Flavoxate hydrochloride

B3433-5.1 10 mM (in 1mL DMSO)
EUR 166
Description: Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.

Flavoxate hydrochloride

B3433-50 50 mg
EUR 363
Description: Flavoxate Hydrochloride(DW-61 Hydrochloride) is a muscarinic AChR antagonist used in various urinary syndromes and as an antispasmodic.

Tiagabine hydrochloride

B3443-10 10 mg
EUR 102

Tiagabine hydrochloride

B3443-5.1 10 mM (in 1mL DMSO)
EUR 108

Lercanidipine hydrochloride

B3482-10 10 mg
EUR 119

Lercanidipine hydrochloride

B3482-100 100 mg
EUR 453

Lercanidipine hydrochloride

B3482-200 200 mg
EUR 592

Lercanidipine hydrochloride

B3482-5.1 10 mM (in 1mL DMSO)
EUR 132

Lercanidipine hydrochloride

B3482-50 50 mg
EUR 313

Sarpogrelate hydrochloride

B3494-10 10 mg
EUR 139
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].

Sarpogrelate hydrochloride

B3494-100 100 mg
EUR 421
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].

Sarpogrelate hydrochloride

B3494-5.1 10 mM (in 1mL DMSO)
EUR 150
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].

Sarpogrelate hydrochloride

B3494-50 50 mg
EUR 322
Description: Ki: 8.39 nMSarpogrelate (MCI-9042) was shown to have the same affinity as ritanserin for 5-HT2A receptors, [1].The blockade of 5-HT2A receptors can inhibit thrombus formation suppresses platelet aggregation and inhibits vascular smooth muscle cell proliferation [2].

Ramosetron Hydrochloride

B3536-10 10 mg
EUR 126

Ramosetron Hydrochloride

B3536-100 100 mg
EUR 661

Ramosetron Hydrochloride

B3536-25 25 mg
EUR 222

Ramosetron Hydrochloride

B3536-50 50 mg
EUR 376

Demeclocycline hydrochloride

B3601-1000 1 g
EUR 174

Demeclocycline hydrochloride

B3601-500 500 mg
EUR 145

Crizotinib hydrochloride

B3608-10 10 mg
EUR 139

Crizotinib hydrochloride

B3608-100 100 mg
EUR 303

Crizotinib hydrochloride

B3608-200 200 mg
EUR 485

Crizotinib hydrochloride

B3608-5.1 10 mM (in 1mL DMSO)
EUR 150

Crizotinib hydrochloride

B3608-50 50 mg
EUR 231

Crizotinib hydrochloride

B3608-500 500 mg
EUR 756

GW311616 hydrochloride

B4676-10 10 mg
EUR 601
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].

GW311616 hydrochloride

B4676-100 100 mg
EUR 2364
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].

GW311616 hydrochloride

B4676-5 5 mg
EUR 435
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].

GW311616 hydrochloride

B4676-5.1 10 mM (in 1mL DMSO)
EUR 583
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].

GW311616 hydrochloride

B4676-50 50 mg
EUR 1703
Description: GW311616 hydrochloride is a potent, selective, intracellular, orally bioavailable and long duration inhibitor of human neutrophil elastase (HNE) with an IC50 value of 22nM [1].

THZ1 Hydrochloride

B4736-10 10 mg
EUR 224
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.

THZ1 Hydrochloride

B4736-25 25 mg
EUR 398
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.

THZ1 Hydrochloride

B4736-5 5 mg
EUR 142
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.

THZ1 Hydrochloride

B4736-5.1 10 mM (in 1mL DMSO)
EUR 171
Description: THZ1 is a covalent inhibitor of CDK7 with IC50 value of 3.2nM [1].THZ1 covalently modifies CDK7 by targeting C312 residue outside of the kinase domain, providing an unanticipated means of achieving covalent selectivity.

ZLN024 hydrochloride

B4840-10 10 mg
EUR 248

ZLN024 hydrochloride

B4840-5 5 mg
EUR 167

ZLN024 hydrochloride

B4840-50 50 mg
EUR 864

SAR407899 hydrochloride

B4909-10 10 mg
EUR 200

SAR407899 hydrochloride

B4909-100 100 mg
EUR 773

SAR407899 hydrochloride

B4909-5 5 mg
EUR 139

SAR407899 hydrochloride

B4909-5.1 10 mM (in 1mL DMSO)
EUR 150

SAR407899 hydrochloride

B4909-50 50 mg
EUR 502

Pronethalol hydrochloride

B5023-100 100 mg
EUR 210

Dihydrexidine hydrochloride

B5028-25 25 mg
EUR 1054

Dihydrexidine hydrochloride

B5028-5 5 mg
EUR 292

Norketamine hydrochloride

B5244-10 10 mg
EUR 226

Norketamine hydrochloride

B5244-50 50 mg
EUR 796

(+)-Igmesine hydrochloride

B5294-10 10 mg
EUR 486
Description: IC50: 19.1 nMJO 1784 is a selective ?1 receptor ligand.The CNS ? receptor ligands, as is known, modulates central neurotransmitter systems ( noradrenergic-, glutaminergic-, and dopaminergic-neurons was included).

(+)-Igmesine hydrochloride

B5294-50 50 mg
EUR 1850
Description: IC50: 19.1 nMJO 1784 is a selective ?1 receptor ligand.The CNS ? receptor ligands, as is known, modulates central neurotransmitter systems ( noradrenergic-, glutaminergic-, and dopaminergic-neurons was included).

DOI hydrochloride

B5321-10 10 mg
EUR 171

DOI hydrochloride

B5321-5 5 mg
EUR 118

DOI hydrochloride

B5321-50 50 mg
EUR 595

DOB hydrochloride

B5344-1 1 mg
EUR 118

Tropisetron Hydrochloride

B1002-1000 1 g
EUR 224
Description: Tropisetron is a selective 5-HT3 receptor antagonist and ?7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor.

Tropisetron Hydrochloride

B1002-500 500 mg
EUR 171
Description: Tropisetron is a selective 5-HT3 receptor antagonist and ?7-nicotinic receptor agonist with an IC50 of 70.1 ± 0.9 nM for 5-HT3 receptor.

XL413 hydrochloride

B1015-10 10 mg
EUR 241
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1

XL413 hydrochloride

B1015-100 100 mg
EUR 838
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1

XL413 hydrochloride

B1015-5 5 mg
EUR 171
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1

XL413 hydrochloride

B1015-50 50 mg
EUR 595
Description: XL413 is a potent and selective Cdc7 inhibitor with an IC50 of 3.7 nM, >60-fold selectivity against CK2, >10-fold selectivity against PIM, and >300-fold selectivity against a panel of over 100 protein kinases. Phase 1

Imeglimin hydrochloride

B1067-10 10 mg
EUR 490
Description: AMP-activated protein kinase (AMPK) acts as an integrator of regulatory signals to monitor systemic and cellular energy status.

Leave a Comment